These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 15767788)

  • 1. Zoledronic acid-related angiogenesis modifications and survival in advanced breast cancer patients.
    Vincenzi B; Santini D; Dicuonzo G; Battistoni F; Gavasci M; La Cesa A; Grilli C; Virzì V; Gasparro S; Rocci L; Tonini G
    J Interferon Cytokine Res; 2005 Mar; 25(3):144-51. PubMed ID: 15767788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Zoledronic acid induces significant and long-lasting modifications of circulating angiogenic factors in cancer patients.
    Santini D; Vincenzi B; Dicuonzo G; Avvisati G; Massacesi C; Battistoni F; Gavasci M; Rocci L; Tirindelli MC; Altomare V; Tocchini M; Bonsignori M; Tonini G
    Clin Cancer Res; 2003 Aug; 9(8):2893-7. PubMed ID: 12912933
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Zoledronic-acid-induced circulating level modifications of angiogenic factors, metalloproteinases and proinflammatory cytokines in metastatic breast cancer patients.
    Ferretti G; Fabi A; Carlini P; Papaldo P; Cordiali Fei P; Di Cosimo S; Salesi N; Giannarelli D; Alimonti A; Di Cocco B; D'Agosto G; Bordignon V; Trento E; Cognetti F
    Oncology; 2005; 69(1):35-43. PubMed ID: 16088233
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biomarker alterations with metronomic use of low-dose zoledronic acid for breast cancer patients with bone metastases and potential clinical significance.
    Zhao X; Xu X; Guo L; Ragaz J; Guo H; Wu J; Shao Z; Zhu J; Guo X; Chen J; Zhu B; Wang Z; Hu X
    Breast Cancer Res Treat; 2010 Dec; 124(3):733-43. PubMed ID: 20882405
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
    Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
    Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fever after zoledronic acid administration is due to increase in TNF-alpha and IL-6.
    Dicuonzo G; Vincenzi B; Santini D; Avvisati G; Rocci L; Battistoni F; Gavasci M; Borzomati D; Coppola R; Tonini G
    J Interferon Cytokine Res; 2003 Nov; 23(11):649-54. PubMed ID: 14651779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Repeated intermittent low-dose therapy with zoledronic acid induces an early, sustained, and long-lasting decrease of peripheral vascular endothelial growth factor levels in cancer patients.
    Santini D; Vincenzi B; Galluzzo S; Battistoni F; Rocci L; Venditti O; Schiavon G; Angeletti S; Uzzalli F; Caraglia M; Dicuonzo G; Tonini G
    Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4482-6. PubMed ID: 17671133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of zoledronic acid on serum angiogenic factors in patients with bone metastases.
    Tas F; Duranyildiz D; Oguz H; Camlica H; Yasasever V; Topuz E
    Med Oncol; 2008; 25(3):346-9. PubMed ID: 18204821
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of zoledronic acid in patients with breast cancer metastatic to bone: a multicenter clinical trial.
    Cartenì G; Bordonaro R; Giotta F; Lorusso V; Scalone S; Vinaccia V; Rondena R; Amadori D
    Oncologist; 2006; 11(7):841-8. PubMed ID: 16880243
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy.
    Clemons MJ; Dranitsaris G; Ooi WS; Yogendran G; Sukovic T; Wong BY; Verma S; Pritchard KI; Trudeau M; Cole DE
    J Clin Oncol; 2006 Oct; 24(30):4895-900. PubMed ID: 17001071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular endothelial growth factor activity after switching of bisphosphonate treatment for metastatic breast cancer.
    Amir E; Trinkaus M; Simmons CE; Dranitsaris G; Clemons MJ
    J Clin Pathol; 2009 May; 62(5):474-6. PubMed ID: 19398598
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial.
    Rosen LS; Gordon D; Tchekmedyian NS; Yanagihara R; Hirsh V; Krzakowski M; Pawlicki M; De Souza P; Zheng M; Urbanowitz G; Reitsma D; Seaman J
    Cancer; 2004 Jun; 100(12):2613-21. PubMed ID: 15197804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Zoledronic acid significantly improves pain scores and quality of life in breast cancer patients with bone metastases: a randomised, crossover study of community vs hospital bisphosphonate administration.
    Wardley A; Davidson N; Barrett-Lee P; Hong A; Mansi J; Dodwell D; Murphy R; Mason T; Cameron D
    Br J Cancer; 2005 May; 92(10):1869-76. PubMed ID: 15870721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in bone resorption and vascular endothelial growth factor after a single zoledronic acid infusion in cancer patients with bone metastases from solid tumours.
    Santini D; Vincenzi B; Hannon RA; Brown JE; Dicuonzo G; Angeletti S; La Cesa A; Coleman RE; Tonini G; Budillon A; Caraglia M; Holen I
    Oncol Rep; 2006 May; 15(5):1351-7. PubMed ID: 16596210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative evaluation of safety and efficacy of pamidronate and zoledronic acid in multiple myeloma patients (single center experience).
    Kraj M; Pogłód R; Maj S; Pawlikowski J; Sokołowska U; Szczepanik J
    Acta Pol Pharm; 2002; 59(6):478-82. PubMed ID: 12669777
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial.
    Kohno N; Aogi K; Minami H; Nakamura S; Asaga T; Iino Y; Watanabe T; Goessl C; Ohashi Y; Takashima S
    J Clin Oncol; 2005 May; 23(15):3314-21. PubMed ID: 15738536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Validity of bone marker measurements for monitoring response to bisphosphonate therapy with zoledronic acid in metastatic breast cancer.
    Aktas B; Kasimir-Bauer S; Lehmann N; Kimmig R; Tewes M
    Oncol Rep; 2013 Jul; 30(1):441-7. PubMed ID: 23604361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pamidronate induces modifications of circulating angiogenetic factors in cancer patients.
    Santini D; Vincenzi B; Avvisati G; Dicuonzo G; Battistoni F; Gavasci M; Salerno A; Denaro V; Tonini G
    Clin Cancer Res; 2002 May; 8(5):1080-4. PubMed ID: 12006522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01/04) randomised open-label phase 3 trial.
    Coleman R; Cameron D; Dodwell D; Bell R; Wilson C; Rathbone E; Keane M; Gil M; Burkinshaw R; Grieve R; Barrett-Lee P; Ritchie D; Liversedge V; Hinsley S; Marshall H;
    Lancet Oncol; 2014 Aug; 15(9):997-1006. PubMed ID: 25035292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical value of bone remodelling markers in patients with bone metastases treated with zoledronic acid.
    Pectasides D; Nikolaou M; Farmakis D; Kanakis I; Gaglia A; Kountourakis P; Karamanos NK; Economopoulos T; Raptis SA
    Anticancer Res; 2005; 25(2B):1457-63. PubMed ID: 15865105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.